newsfilter
← Latest News
PR Newswire·

Genprex to Highlight Dual Delivery Strategy for Diabetes Gene Therapy at Future of Cell and Gene Therapy Symposium

  • Genprex, Inc. announced that Senior Director of Quality Control & Product Development Pier-Anne Lachance will present at Drug Discovery News' Future of Cell & Gene Therapy Symposium on Nov. 17-18, 2026.
  • The presentation titled "Building the Future of Diabetes Gene Therapy: Lessons from Parallel AAV & Lipid-Based Development Programs" will explore scientific, manufacturing, & optimization considerations for two distinct gene delivery approaches.
  • Genprex is evaluating an adeno-associated virus (AAV) approach to deliver Pdx1 & MafA genes to reprogram pancreatic cells, alongside a non-viral lipid-based approach that may allow for repeat dosing.
  • Both diabetes gene therapy programs targeting Type 1 & Type 2 diabetes remain in preclinical development while the company works toward IND-enabling studies.
  • Genprex's lead oncology candidate, REQORSA®, is a non-viral gene therapy delivering the TUSC2 tumor suppressor gene via the ONCOPREX® Delivery System for lung cancer.
  • The FDA has granted Fast Track Designation to both lung cancer programs & Orphan Drug designation to the small cell lung cancer program.
  • Presentation materials will be available on Genprex's website following the conference.
Company
Genprex, Inc.
Keywords
Genprex, Inc.